Guggenheim Capital LLC cut its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 27.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,777 shares of the medical equipment provider’s stock after selling 48,521 shares during the quarter. Guggenheim Capital LLC owned 0.29% of ABIOMED worth $23,761,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Nationwide Fund Advisors lifted its holdings in shares of ABIOMED by 8.0% during the 3rd quarter. Nationwide Fund Advisors now owns 452,879 shares of the medical equipment provider’s stock valued at $76,355,000 after buying an additional 33,621 shares during the period. State of Wisconsin Investment Board lifted its holdings in shares of ABIOMED by 3.6% during the 3rd quarter. State of Wisconsin Investment Board now owns 8,364 shares of the medical equipment provider’s stock valued at $1,410,000 after buying an additional 294 shares during the period. CIBC Asset Management Inc bought a new position in shares of ABIOMED during the 3rd quarter valued at $248,000. New York State Common Retirement Fund lifted its holdings in shares of ABIOMED by 1.9% during the 3rd quarter. New York State Common Retirement Fund now owns 313,590 shares of the medical equipment provider’s stock valued at $52,871,000 after buying an additional 5,719 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of ABIOMED by 12.5% during the 3rd quarter. Rhumbline Advisers now owns 104,316 shares of the medical equipment provider’s stock valued at $17,588,000 after buying an additional 11,571 shares during the period. 88.41% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Andrew J. Greenfield sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total value of $5,407,200.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.00% of the stock is currently owned by company insiders.
ABMD stock opened at $294.01 on Wednesday. ABIOMED, Inc. has a twelve month low of $117.36 and a twelve month high of $304.28. The company has a market capitalization of $12,751.13, a price-to-earnings ratio of 148.49, a P/E/G ratio of 3.99 and a beta of 0.25.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.20. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The company had revenue of $154.00 million for the quarter, compared to analysts’ expectations of $154.00 million. During the same period last year, the firm earned $0.34 EPS. ABIOMED’s revenue for the quarter was up 34.9% compared to the same quarter last year. equities analysts predict that ABIOMED, Inc. will post 2.29 EPS for the current year.
Several research firms have recently weighed in on ABMD. SunTrust Banks reissued a “buy” rating and set a $370.00 price target on shares of ABIOMED in a report on Friday, February 16th. Jefferies Group reissued a “buy” rating and set a $300.00 price target on shares of ABIOMED in a report on Thursday, February 1st. Guggenheim reaffirmed a “buy” rating and issued a $280.00 target price on shares of ABIOMED in a report on Friday, February 2nd. Piper Jaffray Companies reaffirmed a “positive” rating and issued a $300.00 target price (up from $220.00) on shares of ABIOMED in a report on Thursday, February 1st. Finally, Leerink Swann raised their target price on ABIOMED to $300.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. ABIOMED has an average rating of “Buy” and an average target price of $288.86.
COPYRIGHT VIOLATION NOTICE: “Guggenheim Capital LLC Has $23.76 Million Position in ABIOMED, Inc. (ABMD)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://ledgergazette.com/2018/03/21/guggenheim-capital-llc-has-23-76-million-position-in-abiomed-inc-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.